[Infographie] Traitement XAV19

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

[Infographie] Traitement XAV19

Related Posts

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.